Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| continues to be strong |
| Mammography continued to be solid with revenues above the sales trend in the quarter, while radiographic was below its sales trend |
| Global sales of our industrial products in the quarter were solid, but below its sales trend in the quarter |
| We continue to see strong momentum in our cargo inspection business |
| So in that way, that's also positive for the long-term |
| is -- our hospitals are generally doing better from a profitability standpoint, they're cost structure, labor costs and tie to nursing and clinicians as manpower has gotten better, and so they're managing it better |
| In closing, as always, I'm very proud of all the hard work of our employees globally as they work to support our customers every day |
| In summary, we continue to be excited about the prospects for new imaging products like photon counting CT and our unique position to support our customers in bringing innovative systems to market |
| The cargo inspection business, we have good visibility for the rest of the year |
| So, we are -- we feel positive about the U.S |
| So that's clearly a very strong growth we had last year in Industrial |
| So, there's profitability improved |
| So, yes, the comps are going to become -- Industrial, we grew very well last year |
| The broad-based radiology community has picked up on photon counting as a viable technology and clinically exciting for them |
| So that business is doing well |
| We're looking forward to our customer successes with incorporating our technologies and also looking forward to their success this year with new product launches |
| The product is showing well, and we've got a few customers on it, and it's moving forward |
| We had over 150 meetings with our customers and prospects, and it was a very productive business development event for us |
| So that is there because we were initially expecting a little bit better performance from our Industrial segment |
| But in general, we are thinking things will improve because the government does want to spend money on the infrastructure and provide better healthcare facilities and services to its citizens |
| So, there is the positive pressure there along with, we would say, taking care of the healthcare system for the long-term goodness of the system |
| So that generally bodes well for capital availability for diagnostic imaging |
| What we're sensing now is that the audit is -- the audits made substantial progress |
| In industrial, it is still very strong in the cargo inspection area, where we are shipping a lot of hardware or what we call industrial systems or these big linear accelerators or LINACs |
| Again, I know you don't actually go by segment, but you had a great year last year |
| So, we are expecting both of them to pick up at this time, and that should drive a rebound in second half for us |
| We grew 19% year-over-year in 2023 |
| Our gross margin on the service piece is much higher |
| That's going well |
| China was a pretty strong growth area for us, but CT and some other products over there |
| Statement |
|---|
| Non-GAAP gross margin in the first quarter was 31%, which was below our expectations and down approximately 100 basis points compared to the same quarter last year |
| And then the unfavorable mix in Industrial segment drove gross margins down |
| In our Medical segment, global sales of CT tubes were seasonally softer than usual and below its sales trend |
| Fluoroscopy and oncology modalities were weaker in the quarter and were below their respective sales trends |
| So, gross margin, we did see softness in gross margin in Q1, and that was largely driven by unexpected softness in the Industrial segment |
| During the quarter, we experienced unfavorable product mix in both Medical and Industrial segments, along with seasonally low volumes |
| Revenue in the first quarter was down 8% year-over-year |
| The lower-than-expected industrial revenue contributed to lower gross margin in the quarter |
| Gross margin of 31% was down 100 basis points compared to the first quarter of fiscal 2023 |
| As highlighted last quarter, the decline in APAC was primarily the result of lower sales in our China business due to the government's anticorruption campaign into its healthcare system |
| First quarter revenues decreased 8% compared to the first quarter of fiscal 2023 |
| Net earnings were $2 million or $0.06 per diluted share, down $0.15 year-over-year |
| James Sidoti So, if I look at the guidance, you're expecting revenue to be down again in the second quarter, and I assume that's largely due to the situation in China |
| Our revenues were at the midpoint of guidance, while gross margin was below the guided range and non-GAAP EPS was lower than the guidance midpoint |
| Outside of cargo, we're experiencing softness in industrial end markets, particularly in semiconductor, automotive and electronics |
| Overall, volume in Industrial -- overall volume for the business is quite low at $190 million for the full company |
| First quarter gross margin was 30%, 100 basis points lower year-over-year |
| Right now, we are seeing softness in non-cargo domains of Industrial, particularly in semiconductors, automotive and electronics related applications where our product is sold in the Industrial segment |
| So, between China and Industrial and the mix on the Industrial is bringing the gross margins down, which we expect to rebound or recover in the second half, and that's what we are expecting right now |
| Operating income was $10 million, down $8 million compared to the same quarter last year |
Please consider a small donation if you think this website provides you with relevant information